PCSA today
$1.85-$0.02 (-1.07%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourBearish
1 hourExpanding
15 minBullish
5 minConsolidating
Daily trend turns up above $3.11
Key levels
Resistance$2.28
Resistance$2.10
Support$1.85
Support$1.67
Latest news & SEC filings
NewsProcessa Pharmaceuticals Names New Executives to Leadership Team
All PCSA news →About Processa Pharmaceuticals
Processa Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for cancer and other diseases. Its main cancer candidates include NGC-Cap, a combination therapy for solid tumors such as breast and colorectal cancer, and NGC-Iri, a preclinical compound for lung, pancreatic, ovarian, and other solid tumors. The company also has non-oncology candidates, PCS12852 for gastroparesis and PCS499 for primary glomerular disease, which it is exploring for out-licensing or partnership. It operates in the United States.
Based on the company's 10-K filed Mar 18, 2026.
Nasdaq · Healthcare
Processa Pharmaceuticals, Inc. (PCSA)
What Is the Price Target for PCSA?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is PCSA a Buy or Sell Right Now?
Thesis
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PCSA.
Start Free Trial →Is PCSA Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/B, PEG
Fair Value
$1.45
15
Moat Score
NONE
4/9
Piotroski Score
-23.0
Altman Z-Score
What Is Smart Money Doing with PCSA?
Insider Signal
BUYING
20 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Young David | director officer | Buy | 1,786 | $5K | May 29, 2026 |
| SKIBSTED RUSSELL | officer | Buy | 2,292 | $6K | May 29, 2026 |
| Ng George K | director officer | Buy | 2,129 | $5K | May 29, 2026 |
| Lin Patrick | officer | Buy | 1,582 | $4K | May 29, 2026 |
| Guy Wendy | officer | Buy | 1,829 | $5K | May 29, 2026 |
| Ng George K | director officer | Buy | 1,843 | $5K | May 15, 2026 |
| Young David | director officer | Buy | 1,545 | $5K | May 15, 2026 |
| Lin Patrick | officer | Buy | 1,369 | $4K | May 15, 2026 |
| Guy Wendy | officer | Buy | 1,583 | $5K | May 15, 2026 |
| SKIBSTED RUSSELL | officer | Buy | 1,984 | $6K | May 15, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →PCSA Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
89.3%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for PCSA
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for PCSA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 15:18:18 | $1.80 | 2,000 | $$4K | SELL |
| 14:49:21 | $1.85 | 1,000 | $$2K | SELL |
| 20:21:33 | $1.85 | 11,906 | $$22K | SELL |
| 18:12:30 | $1.85 | 4,230 | $$8K | BUY |
| 20:50:01 | $1.93 | 1,300 | $$3K | BUY |
5 dark pool trades shown · $$38K preview volume
Real-time institutional flow, block trades, and net positioning
What Traders Are Saying About PCSA
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for PCSA. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
$PCSA has an event on Thu Nov 12.
Join 3,500+ traders discussing PCSA in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Processa Pharmaceuticals, Inc. (PCSA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →PCSA — frequently asked questions
What is PCSA stock price today?
Processa Pharmaceuticals, Inc. (PCSA) is at $1.85, down 1.07% (-$0.02) at the Nov 12, 2026 close.
Why is PCSA stock moving today?
Latest PCSA news — Nov 5, 2026: Processa Pharmaceuticals Names New Executives to Leadership Team
Did PCSA beat earnings?
PCSA last reported on Aug 13, 2026: EPS -$1.19 vs -$1.00 expected — a miss of 19.0%.
Does PCSA pay a dividend?
PCSA does not currently pay a dividend.
What are PCSA support and resistance levels?
Support: $1.85, $1.67, $1.50. Resistance: $2.10, $2.28, $2.46.
What are insiders doing with PCSA?
Insider activity: BUYING, 20 buys and 0 sells in the last 90 days.
What is the latest news on PCSA?
Nov 5, 2026: Processa Pharmaceuticals Names New Executives to Leadership Team